Logo image of ISRG

INTUITIVE SURGICAL INC (ISRG) Stock Fundamental Analysis

NASDAQ:ISRG - Nasdaq - US46120E6023 - Common Stock - Currency: USD

482.74  +1.4 (+0.29%)

After market: 482.74 0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ISRG. ISRG was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making ISRG a very profitable company, without any liquidiy or solvency issues. ISRG is not overvalued while it is showing excellent growth. This is an interesting combination. This makes ISRG very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year ISRG was profitable.
In the past year ISRG had a positive cash flow from operations.
ISRG had positive earnings in each of the past 5 years.
ISRG had a positive operating cash flow in each of the past 5 years.
ISRG Yearly Net Income VS EBIT VS OCF VS FCFISRG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

1.2 Ratios

The Return On Assets of ISRG (12.39%) is better than 94.21% of its industry peers.
ISRG's Return On Equity of 14.05% is amongst the best of the industry. ISRG outperforms 89.47% of its industry peers.
ISRG has a better Return On Invested Capital (12.81%) than 95.26% of its industry peers.
ISRG had an Average Return On Invested Capital over the past 3 years of 12.30%. This is above the industry average of 7.68%.
The 3 year average ROIC (12.30%) for ISRG is below the current ROIC(12.81%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.39%
ROE 14.05%
ROIC 12.81%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.18%
ROE(5y)12.95%
ROIC(3y)12.3%
ROIC(5y)11.92%
ISRG Yearly ROA, ROE, ROICISRG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

With an excellent Profit Margin value of 27.81%, ISRG belongs to the best of the industry, outperforming 96.32% of the companies in the same industry.
In the last couple of years the Profit Margin of ISRG has declined.
With an excellent Operating Margin value of 28.14%, ISRG belongs to the best of the industry, outperforming 96.32% of the companies in the same industry.
In the last couple of years the Operating Margin of ISRG has declined.
ISRG's Gross Margin of 67.46% is fine compared to the rest of the industry. ISRG outperforms 72.63% of its industry peers.
ISRG's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.14%
PM (TTM) 27.81%
GM 67.46%
OM growth 3Y-4.3%
OM growth 5Y-1.74%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
ISRG Yearly Profit, Operating, Gross MarginsISRG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

ISRG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ISRG has more shares outstanding than it did 1 year ago.
ISRG has more shares outstanding than it did 5 years ago.
ISRG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ISRG Yearly Shares OutstandingISRG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ISRG Yearly Total Debt VS Total AssetsISRG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.43
WACC8.98%
ISRG Yearly LT Debt VS Equity VS FCFISRG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

A Current Ratio of 5.22 indicates that ISRG has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.22, ISRG is doing good in the industry, outperforming 75.79% of the companies in the same industry.
ISRG has a Quick Ratio of 4.54. This indicates that ISRG is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.54, ISRG is doing good in the industry, outperforming 77.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.22
Quick Ratio 4.54
ISRG Yearly Current Assets VS Current LiabilitesISRG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.37% over the past year.
Measured over the past years, ISRG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.48% on average per year.
Looking at the last year, ISRG shows a quite strong growth in Revenue. The Revenue has grown by 17.24% in the last year.
ISRG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.27% yearly.
EPS 1Y (TTM)28.37%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%38.12%
Revenue 1Y (TTM)17.24%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%25.16%

3.2 Future

ISRG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.44% yearly.
Based on estimates for the next years, ISRG will show a quite strong growth in Revenue. The Revenue will grow by 13.47% on average per year.
EPS Next Y11.93%
EPS Next 2Y14.76%
EPS Next 3Y15.12%
EPS Next 5Y14.44%
Revenue Next Year17.28%
Revenue Next 2Y16.42%
Revenue Next 3Y15.94%
Revenue Next 5Y13.47%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ISRG Yearly Revenue VS EstimatesISRG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
ISRG Yearly EPS VS EstimatesISRG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ISRG is valuated quite expensively with a Price/Earnings ratio of 65.86.
ISRG's Price/Earnings ratio is a bit cheaper when compared to the industry. ISRG is cheaper than 66.84% of the companies in the same industry.
When comparing the Price/Earnings ratio of ISRG to the average of the S&P500 Index (28.29), we can say ISRG is valued expensively.
Based on the Price/Forward Earnings ratio of 58.84, the valuation of ISRG can be described as expensive.
69.47% of the companies in the same industry are more expensive than ISRG, based on the Price/Forward Earnings ratio.
ISRG is valuated expensively when we compare the Price/Forward Earnings ratio to 21.08, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 65.86
Fwd PE 58.84
ISRG Price Earnings VS Forward Price EarningsISRG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ISRG is valued a bit cheaper than 65.79% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ISRG is valued a bit cheaper than 68.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 132.65
EV/EBITDA 57.58
ISRG Per share dataISRG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ISRG has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ISRG's earnings are expected to grow with 15.12% in the coming years.
PEG (NY)5.52
PEG (5Y)5.74
EPS Next 2Y14.76%
EPS Next 3Y15.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ISRG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTUITIVE SURGICAL INC

NASDAQ:ISRG (4/17/2025, 8:00:02 PM)

After market: 482.74 0 (0%)

482.74

+1.4 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-23 2025-01-23/amc
Earnings (Next)04-22 2025-04-22/amc
Inst Owners89.44%
Inst Owner Change0.01%
Ins Owners0.5%
Ins Owner Change5.51%
Market Cap172.95B
Analysts79.49
Price Target644.51 (33.51%)
Short Float %1.36%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.57%
Min EPS beat(2)10.37%
Max EPS beat(2)20.76%
EPS beat(4)4
Avg EPS beat(4)12.24%
Min EPS beat(4)4.44%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)7.68%
EPS beat(12)10
Avg EPS beat(12)4.92%
EPS beat(16)13
Avg EPS beat(16)7.19%
Revenue beat(2)1
Avg Revenue beat(2)2.49%
Min Revenue beat(2)-0.14%
Max Revenue beat(2)5.12%
Revenue beat(4)1
Avg Revenue beat(4)1.04%
Min Revenue beat(4)-0.76%
Max Revenue beat(4)5.12%
Revenue beat(8)3
Avg Revenue beat(8)0.53%
Revenue beat(12)5
Avg Revenue beat(12)0%
Revenue beat(16)7
Avg Revenue beat(16)1.66%
PT rev (1m)-1.3%
PT rev (3m)10.8%
EPS NQ rev (1m)-0.74%
EPS NQ rev (3m)-2.83%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)2.21%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.79%
Valuation
Industry RankSector Rank
PE 65.86
Fwd PE 58.84
P/S 20.71
P/FCF 132.65
P/OCF 71.62
P/B 10.46
P/tB 10.69
EV/EBITDA 57.58
EPS(TTM)7.33
EY1.52%
EPS(NY)8.2
Fwd EY1.7%
FCF(TTM)3.64
FCFY0.75%
OCF(TTM)6.74
OCFY1.4%
SpS23.31
BVpS46.14
TBVpS45.17
PEG (NY)5.52
PEG (5Y)5.74
Profitability
Industry RankSector Rank
ROA 12.39%
ROE 14.05%
ROCE 14.22%
ROIC 12.81%
ROICexc 27.51%
ROICexgc 28.82%
OM 28.14%
PM (TTM) 27.81%
GM 67.46%
FCFM 15.61%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.18%
ROE(5y)12.95%
ROIC(3y)12.3%
ROIC(5y)11.92%
ROICexc(3y)22.09%
ROICexc(5y)21.23%
ROICexgc(3y)23.21%
ROICexgc(5y)22.47%
ROCE(3y)13.65%
ROCE(5y)13.23%
ROICexcg growth 3Y10.09%
ROICexcg growth 5Y3.3%
ROICexc growth 3Y10.33%
ROICexc growth 5Y3.99%
OM growth 3Y-4.3%
OM growth 5Y-1.74%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 222.37%
Cap/Sales 13.3%
Interest Coverage 250
Cash Conversion 84.73%
Profit Quality 56.14%
Current Ratio 5.22
Quick Ratio 4.54
Altman-Z N/A
F-Score7
WACC8.98%
ROIC/WACC1.43
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.37%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%38.12%
EPS Next Y11.93%
EPS Next 2Y14.76%
EPS Next 3Y15.12%
EPS Next 5Y14.44%
Revenue 1Y (TTM)17.24%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%25.16%
Revenue Next Year17.28%
Revenue Next 2Y16.42%
Revenue Next 3Y15.94%
Revenue Next 5Y13.47%
EBIT growth 1Y32.03%
EBIT growth 3Y8.64%
EBIT growth 5Y11.3%
EBIT Next Year37.77%
EBIT Next 3Y23.18%
EBIT Next 5Y19.91%
FCF growth 1Y73.93%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y33.15%
OCF growth 3Y4.95%
OCF growth 5Y8.61%